



Date: 30-05-2025

**To,
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.**

Dear Sir(s),

**Sub: Outcome of Board Meeting -Disclosure under Reg.30 of SEBI (LODR) Regulations, 2015
Scrip Code: 524636**

Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Schedule III to the said Regulations, this is to inform you that the Board of Directors of the Company, at their meeting held on Friday, 30th May, 2025, inter alia, transacted the following items of business:

1. Considered and approved the Audited Financial Results for the fourth quarter and Financial Year Ended 31st March, 2025. The said Audited Financial Results were reviewed by the Audit Committee and thereafter approved by the Board of Directors.
2. Considered and approved the Shifting of the Corporate Office of the Company within the local limits of city i.e. **FROM** "Plot No 43 The Park View 1st Floor, Lumbini Avenue, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032 **TO** Level-1, Plot No. B1 and B2, IDA Gandhi Nagar, Kukatpally, Hyderabad-500037, Telangana, India., with effect from May 30, 2025.

The Board Meeting of the Company commenced at 6.00 PM and concluded at 7.00 P.M.

This is for your information and records.

Regards,
For Oxygenta Pharmaceutical Limited

Dolly Lakhichand Mandhan
Company Secretary & Compliance Officer
M.No.: A66040

OXYGENTA PHARMACEUTICAL LIMITED

CIN: L24110TG1990PLC012038

Statement of Audited Financial Results for the Quarter and Year ended 31st March,2025

(in Rs Lakhs)

S.No	Particulars	Quarter ended			Year ended	
		March 31,2025	December 31,2024	March 31, 2024	March 31,2025	March 31,2024
		Audited	Un Audited	Audited	Audited	Audited
1	Income					
	a. Revenue from operations	4,946.66	3,320.61	1,055.24	10929.86	3964.21
	b. Other income	4.91	48.82	1.28	130.91	4.24
2	Total Income (a+b)	4,951.56	3369.43	1056.52	11060.77	3968.45
3	Expenses					
	a) Cost of Material Consumed	4,402.97	3,760.65	904.17	10,023.06	3505.52
	b) Change in Inventories	(24.34)	(576.22)	(211.74)	(376.06)	(152.68)
	c) Direct Manufacturing Expenses	344.36	320.95	(147.16)	1,116.09	743.85
	d) Employee benefits expense	218.97	183.28	524.69	689.94	599.37
	e) Finance costs	212.82	38.83	59.49	361.42	266.07
	f) Depreciation and amortization expense	(23.37)	70.60	63.82	178.16	159.39
	g) Other expenses	168.05	67.52	146.70	471.27	237.80
	h) Prior Period Expenses	5.02	-	-	5.02	-
	Total Expenses	5,304.48	3,865.61	1,339.97	12,468.91	5,359.32
4	Profit before exceptional items and tax (2-3)	(352.92)	(496.19)	(283.45)	(1,408.14)	(1,390.87)
5	Exceptional items	27.00	-	(24.74)	27.00	(3.70)
6	Profit before Tax (4-5)	(379.93)	(496.19)	(258.71)	(1,435.14)	(1,387.17)
7	Tax expense					
	(1) Current tax	0.00	0.00	0.00	0	0.00
	(2) Deferred tax	(180.59)	(103.36)	(1,060.29)	(421.27)	(1,039.24)
	(3) Previous year Income tax adjustment	15.96	0	-	15.96	0.00
8	Net Profit/(Loss) for the Period (4-5)	(215.29)	(392.83)	801.58	(1,029.83)	(347.93)
9	Other comprehensive income (OCI)					
	(a) (i) Items that will not be reclassified to profit or loss	10.73	0.00	(7.11)	10.73	(7.11)
	(ii) Tax on items that will not be reclassified to profit or loss	-	0.00	-	0	-
	(b) (i) Items that will be reclassified to profit or loss	-	0.00	-	0	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	0.00	-	0	-
	Total Other Comprehensive income	10.73	-	(7.11)	10.73	(7.11)
10	Total Comprehensive income (6+7)	(226.02)	(392.83)	808.69	(1,040.56)	(340.82)
	Earnings per equity share					
	(Face value of Rs.10/- each)					
	(1) Basic	(0.60)	(1.07)	2.55	(2.86)	(1.09)
	(2) Diluted	(0.60)	(1.12)	2.44	(2.86)	(1.04)
	Paid- up equity share capital(Face Value of Rs.10/- each)	3,698.35	3,698.35	3,348.35	3698.35	3,348.35

Sai Sudhakar



Notes:

- 1.The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules,2016.
- 2.In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been audited by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on Friday, May 30th, 2025.
3. Total Revenue for the current quarter reported Rs 4946.66 Lakhs compared to Rs. 1055.24 lakhs for the corresponding quarter of the previous year.
4. The Loss before tax for the current quarter is Rs.379.93 Lakhs compared to Loss Before tax of Rs.258.71 Lakhs for the corresponding quarter of the previous year.
- 5.The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
- 6.The results for the quarter ended 30th May 2025 are also available on the BSE Ltd website and on the Company's website.
- 7.Figures for the previous periods /year have been regrouped/reclassified wherever necessary.
8. The Company is actively working to complete the identification of its MSME creditors, though a few gaps remain in this process. To facilitate accurate identification, we have requested all suppliers to submit self-declaration forms confirming their MSME status. The Company is currently in the process of collecting these declarations from suppliers to enhance accuracy in reporting.
9. The Company has yet to implement a bill-to-bill adjustment process, which has posed challenges in preparing a precise aging schedule for its creditors. Addressing these outstanding issues remains a priority, and the Company is committed to achieving full compliance and transparency in its reporting.
10. The Company has Created The Exptected Credit Loss Provision amounting 77.23 Lakhs during the year based on the previous Performance of the debtors
11. The figures for the quarter ended March 31, 2025 and March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditor of the Company.
12. The Exceptional items amounts to 27 lakhs as on 31st March 2025 includes the total amount of provident fund damages


for and on behalf of the Board of Directors of
OXYGENTA PHARMACEUTICAL LIMITED
CIN: L24110TG1990PLC012038

V Sai Sudhakar

Place:Hyderabad
Date:30.05.2025

Dr V Sai Sudhakar
Managing Director & CFO
DIN 00733001



<p style="text-align: center;">OXYGENTA PHARMACEUTICAL LIMITED CIN: L24110TG1990PLC012038 Statement of Assets and Liabilities as at March 31, 2025 (All amounts are in INR Lakhs, except for share data and where otherwise stated)</p>			
Particulars	Note	As at March 31, 2025(Audited)	As at March 31, 2024 (Audited)
I. ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	3,683.04	2,935.84
(b) Other intangible assets		-	-
(c) Capital work in progress	3	23.43	-
(d) Goodwill		-	-
(e) Right-of-use assets		-	-
(f) Financial assets		-	-
(i) Investments	4A	4.94	4.94
(ii) Loans	4B	-	41.94
(iii) Trade Receivables	8	108.30	-
(iv) Other financial assets	5	68.10	52.61
(g) Deferred tax assets (net)	6	1,298.34	873.30
(h) Other non-current assets		-	-
Total non-current assets		5,186.15	3,908.62
Current assets			
Inventories	7	2,051.30	1,371.65
(a) Financial assets			
(i) Trade receivables	8	509.80	736.06
(ii) Cash and cash equivalents	9	0.17	0.17
(iii) Bank balances other than Cash and cash equivalents		12.01	9.91
(iv) Other financial assets		-	-
(b) Other current assets	10	521.01	292.80
Total Current Assets		3,094.29	2,410.59
TOTAL ASSETS		8,280.44	6,319.22
II. EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	11	3,698.35	3,348.35
(b) Other equity	12	(6,262.40)	(5,360.59)
Total equity		(2,564.05)	(2,012.24)
Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	13A	2,152.24	4,900.17
(ii) Lease liabilities		-	-
(b) Provisions	14A	107.51	61.78
(c) Deferred Tax Liabilities		-	-
Total non-current Liabilities		2,259.75	4,961.95
Current liabilities			
(a) Financial liabilities			
(i) Borrowings	13B	4,071.00	823.20
(ii) Lease liabilities		-	-
(iii) Trade payables	15	-	-
(a) Total outstanding dues of micro and small enterprises		648.26	330.78
(b) Total outstanding dues of creditors other than micro and small enterprises		2,331.13	1,957.95
(iii) Other financial liabilities		-	-
(b) Other current liabilities	16	1,511.34	250.41
(c) Provisions	14B	23.01	7.16
Total current liabilities		8,584.74	3,369.51
TOTAL EQUITY AND LIABILITIES		8,280.44	6,319.21
<p style="text-align: right;">for and on behalf of the Board of Directors of OXYGENTA PHARMACEUTICAL LIMITED CIN: L24110TG1990PLC012038</p> <div style="display: flex; justify-content: space-between; align-items: center;"> <div> <p>Place: Hyderabad Date: 30th May, 2025</p> </div> <div style="text-align: center;"> <p><i>V Sai Sudhakar</i></p> <p>Dr V Sai Sudhakar Managing Director & CFO DIN 00733001</p> </div> <div style="text-align: right;">  </div> </div>			

OXYGENTA PHARMACEUTICAL LIMITED
CIN: L24110TG1990PLC012038
Statement of Cash Flows for the Period ended March 31, 2025

(All amounts are in INR Lakhs, except for share data and where otherwise stated)

Particulars	Period ended March 31, 2025 (Audited)	Year ended March 31, 2024 (Audited)
I CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	(1,435.14)	(1,387.17)
Adjustments for:		
Depreciation and amortisation expenses	361.42	266.07
Finance costs	178.16	159.39
Interest income	(2.25)	(1.78)
Other Income	(128.66)	-
Provision for bad and doubtful debts	77.23	-
Forex Loss/ (gain)	-	(1.35)
Provision for gratuity and leave encashment	42.60	8.46
Operating profit before working capital changes	(906.63)	(956.37)
Working capital changes:		
(Increase)/Decrease in Trade receivables	117.95	319.58
(Increase) in Other financial assets	26.45	-
Decrease in Other current assets	(228.21)	10.72
(Increase)/Decrease in Inventories	(679.65)	(201.14)
(Increase)/Decrease in Other non current assets	-	(4.65)
(Decrease) in Trade payables	690.65	(395.72)
Increase/(Decrease) in Other current liabilities	1,260.93	-
Increase/(Decrease) in Other financial liabilities	-	(80.18)
Increase/(Decrease) in Provisions	(5.25)	2.80
Cash generated from operations	276.24	(1,304.96)
Income taxes received/(paid)	(15.96)	-
Net cash generated from operating activities	260.28	(1,304.96)
II CASH FLOW FROM INVESTING ACTIVITIES		
Payment for property plant and equipment and CWIP	(1,139.15)	(410.57)
Proceeds from sale of property plant and equipment and CWIP	12.00	-
Interest received on fixed deposits	2.25	1.78
Movement in other bank balances and bank deposits with maturity period of more than three months	-	-
Net cash generated from/(used in) investing activities	(1,124.91)	(408.78)
III CASH FLOW FROM FINANCING ACTIVITIES		
Interest paid	(178.16)	(159.39)
Repayment of lease liabilities	-	-
Proceeds from issuing shares	545.00	2,892.33
Proceeds from issuing other equity instruments	-	56.25
Increase/(decrease) from Long term borrowings	(2,747.92)	(1,075.98)
Increase/(decrease) from Short term borrowings	3,247.80	-
Net cash generated from/(used in) financing activities	866.71	1,713.20
IV Net increase in cash and cash equivalents	2.09	(0.54)
Cash and cash equivalents at the beginning of the year	10.08	10.62
Cash and cash equivalents at the end of the year	12.17	10.08

for and on behalf of the Board of Directors of
OXYGENTA PHARMACEUTICAL LIMITED
CIN: L24110TG1990PLC012038

V Sai Sudhakar



Place: Hyderabad
Date: 30th May, 2025

Dr V Sai Sudhakar
Managing Director & CFO
DIN 00733001

Date: 30th May 2025

To
Corporate Relations Department
BSE Limited
P.J. Towers, Dalal Street,
Mumbai-400001

Dear Sir,

Sub: Declaration Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.

**Ref No. Scrip Code: 524636
DECLARATION FOR UNMODIFIED OPINION**

I, Sai Sudhakar Vankineni, Managing Director of M/s. Oxygenta Pharmaceutical Limited having its Registered office at No.252/1, Aroor village, Sadasivapet Mandal, Medak District, Telangana, India, hereby declare that, M/s. A M Reddy & D R Reddy, Statutory Auditors of the Company, have issued an Audit Report with Unmodified Opinion on Standalone Audited Financial Results for the Quarter and Year Ended 31st March, 2025.


This Declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (LODR) Regulations 2015 as amended.

Thanking You,
Yours Faithfully,

For Oxygenta Pharmaceutical Limited



Name: Sai Sudhakar Vankineni
Designation: Managing Director
DIN.: 00733001





Independent Auditor's Review Report on Audited Quarterly Financial results of OXYGENTA PHARMACEUTICALS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Oxygenta Pharmaceuticals Limited.

Report on the audit of Standalone Financial Results

Opinion

We have audited the accompanying "Statement of Audited Standalone Financial Results for the quarter and year ended 31 March 2025" ("Statement") of OXYGENTA PHARMACEUTICALS LIMITED (the "Company"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results"

*H.O #14/186, Flat 203, Ananth Sai Residency kamalnagar, Anantapur 515 001 | Phone No: 08554-231666
B.O H.No 3-6-640/1/C, Fourth Floor, Street No 9, Himayat Nagar, Hyderabad 500 029 | Phone No : 040-40077393
Mobile No: 9848032382 Email ID: rkreddy1999@yahoo.com*

section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section-133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

*H.O #14/186, Flat 203, Ananth Sai Residency kamalnagar, Anantapur 515 001 | Phone No: 08554-231666
B.O H.No 3-6-640/11C, Fourth Floor, Street No 9, Himayat Nagar , Hyderabad 500 029 | Phone No : 040-40077393
Mobile No: 9848032382 Email ID: rkreddy1999@yahoo.com*

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
4. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For A.M REDDY & D.R REDDY

Chartered Accountants

Firms Registration No: 009068S



D. Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: 25209211BMJBOC3139

Place: Hyderabad

Date: May 30, 2025

